BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 ...

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...